We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Tempus AI (TEM - Free Report) is expected to reveal quarterly loss of -$0.02 per share, indicating an increase of 88.9% compared to the year-ago period. Analysts forecast revenues of $366.8 million, representing an increase of 82.8% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Tempus metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Revenue- Data and services' of $98.70 million. The estimate suggests a change of +23% year over year.
According to the collective judgment of analysts, 'Net Revenue- Genomics' should come in at $262.05 million. The estimate indicates a year-over-year change of +117.6%.
Analysts' assessment points toward 'Non-GAAP Gross Profit- Genomics' reaching $159.93 million. The estimate is in contrast to the year-ago figure of $59.76 million.
It is projected by analysts that the 'Non-GAAP Gross Profit- Data and Services' will reach $73.47 million. The estimate compares to the year-ago value of $64.40 million.
Over the past month, shares of Tempus have returned -14% versus the Zacks S&P 500 composite's -0.8% change. Currently, TEM carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Tempus AI (TEM - Free Report) is expected to reveal quarterly loss of -$0.02 per share, indicating an increase of 88.9% compared to the year-ago period. Analysts forecast revenues of $366.8 million, representing an increase of 82.8% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Tempus metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Revenue- Data and services' of $98.70 million. The estimate suggests a change of +23% year over year.
According to the collective judgment of analysts, 'Net Revenue- Genomics' should come in at $262.05 million. The estimate indicates a year-over-year change of +117.6%.
Analysts' assessment points toward 'Non-GAAP Gross Profit- Genomics' reaching $159.93 million. The estimate is in contrast to the year-ago figure of $59.76 million.
It is projected by analysts that the 'Non-GAAP Gross Profit- Data and Services' will reach $73.47 million. The estimate compares to the year-ago value of $64.40 million.
View all Key Company Metrics for Tempus here>>>Over the past month, shares of Tempus have returned -14% versus the Zacks S&P 500 composite's -0.8% change. Currently, TEM carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .